Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 22, 2023
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
[ Thu, Jun 22nd 2023
] - WOPRAI
Charles Duncan Reiterated (AXSM) at Buy and Held Target at $104 on, Jun 22nd, 2023
Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $104 on, Jun 22nd, 2023.
Charles has made no other calls on AXSM in the last 4 months.
There are 4 other peers that have a rating on AXSM. Out of the 4 peers that are also analyzing AXSM, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $90 on, Monday, June 12th, 2023
These are the ratings of the 3 analyists that currently disagree with Charles
- Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $110 on, Thursday, June 15th, 2023
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $95 on, Wednesday, June 14th, 2023
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $200 on, Thursday, May 11th, 2023
